how does the eu regulatory network …...an agency of the european union how does the eu regulatory...
TRANSCRIPT
An agency of the European Union
How does the EU Regulatory Network communicates about risk minimisation?
PCWP/HCPWP Workshop on risk minimisation measures - 16 September 2015
Viola Macolić-Šarinić, Agency for Medicinal Products and Medical Devices (HALMED), (Croatia)
Juan Garcia-Burgos, European Medicines Agency (EMA)
Introduction
• New legislation in pharmacovigilance: – Unprecedented focus on (safety) communication by regulatory authorities
– Communication as a key instrument for risk minimisation
– environment of enhanced openness and transparency
1
• Risk communication:
– part of risk assessment and risk minimisation
– clear messages - right audience - right time
– tailored to audiences - appropriate tools and language
– always in context- benefit
– always address uncertainties
– use of quantitative measures
– Involve users of medicines - preparation
– Measure effectiveness
2
Communicating within the EU Regulatory Network
EMA does not target individual EU patients and healthcare professionals, instead:
– Strong coordination with EU Member States
– EU patients and health professionals receive clear, timely and consistent messages on
the safety of their medicines
– Strong collaboration with patients and healthcare professionals'’ organisations
3
Target audiences
Communication about risk minimisation issued by regulators:
– Primary target audience: patients and healthcare professionals
– Media
– Health ministries, public and private health bodies
– Others
4
Information made available at central level
• ‘Product Information’ kept up-to-date (and multilingual) for all medicines centrally authorised
– Reference source for routine minimisation measures
– aligned with additional measures
• Dear Health Care Professional Communication (DHPC)
– not published at central level
• EMA safety communications
• Information on Risk Management Plans
– e.g. RMP summaries
• Information on PSURs assessment & signals
5
EMA safety communication
Start of safety review by PRAC
PRAC recommendation
CHMP/CMD(h)
6
EMA safety communication
7
Direct healthcare professional communication (DHPC)
• Involves both industry and regulators
– important safety information
– delivered directly to individual healthcare professionals
– Ask them to take actions or adapt their practices
• Process has been streamlined – clear criteria applies
• DHPCs agreed at EU level involve PRAC
8
Summary of risk management plan
9
Summary of risk management plan
10
Input from patients, consumers and healthcare professionals
• Individuals nominated by ‘EU Network of eligible organisations’:
− through PCWP and HCPWP
− No financial support available
• Help us in:
− Designing and adapting communication tools
− Preparation of actual communication materials
− Dissemination of key information timely among members
• Excellent feedback and experience.
11
Patient input – EMA safety communication
12
Patient input - EMA safety communication
13
Patient/healthcare professional input
Example: Combined Hormonal Contraceptives (CHCs)
European Society of Gynaecology
European association of general practitioners
European association of consumers (BEUC)
European Institute of women’s health
Positive feedback on pre-tested messages
14
15
16
17
18
EM
A
NC
As
HC
Ps
MA
Hs
PRAC
CHMP
MAH
Patients
MAH(s)
Patients
Patients
HCPs
HCP
DHPC and
communication
plan (in English)
Submission of
translated DHPC
to the NCAs
Dissemination of
DHPC
Implemetation of the
communicated
issues
Communication plan
18
19
Challenges
• Translation of the DHCP – timelines and collaboration with the
MAHs
• Collaboration between MAHs to issue one DHCP
• Dissemination of the DHCP
• Availability of the information for HCPs and patients
• Impact of the DHCP to clinical practice?
19
20
NCAs need
PhV dedicated person for safety
communication and strong PR team
20
DHCP in a case of a referral
Example
21
22
23
24
25
26
Dissemination and availability of the DHPC
Example
27
28
29 Ivabradine – 2 DHPCs
E-prescription system (GP software/health database)
29
1
. 2
.
30
Collaboration with patient organisations
31
32
http://www.rijetke-bolesti.hr/
Croatian patient organisation for rare diseases
32
33 http://www.rijetke-bolesti.hr/
Croatian patient organisation for rare diseases
33
Educational materials
Have to be approved nationally
34
35
36
Other ways of communication
The theatre example
37
38
You should talk
about and report
side effects of
your medicines
What are
side effects?
Antiepileptics 39
Questions?
40
Thank you for your attention
Further information
Agencija za lijekove i medicinske proizvode
Ksaverska cesta 4, 10 000 Zagreb
Tel.: +385 1 4884 100 (centrala) • Faks: +385 1 4884 110
E-pošta: [email protected]
www.halmed.hr